Examination about Hb cycling and the C.E.R.A. given dose in the C.E.R.A. 1-time medication per week in hemodialysis patients

Examination about Hb cycling and the C.E.R.A. given dose in the C.E.R.A. 1-time medication per week in hemodialysis patients - Effect of weekly C.E.R.A.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015041

Enrollment

Registered

2014-09-03

Start date

2015-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic renak failure

Interventions

Change to the 1-time C.E.R.A.medication per week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: undergoing three times dialysis per week three months or more

Exclusion criteria

Exclusion criteria: woman under pregnancy and breast-feeding, myocardial infarction, pulmonary infarction, and cerebral infarction malignant tumor, serious illness infection, blood dyscrasia, hemolytic anemia, or gastrointestinal bleeding beyond AST100 IU/L or beyond ALT100 U/L

Design outcomes

Primary

Measure	Time frame
Decrease of C.E.R.A. total given dose	—

Secondary

Measure	Time frame
Decrease of blood Hepcidin concentration	—

Countries

Japan

Contacts

Public ContactYoshiyuki Oshiro

Kawasaki Medical School Department of General Internal Medicine 1

y-oshiro@med.kawasaki-m.ac.jp086-225-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026